<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179463</url>
  </required_header>
  <id_info>
    <org_study_id>KW-NeoCT-Evaluation-2014</org_study_id>
    <secondary_id>D141100000414004</secondary_id>
    <nct_id>NCT02179463</nct_id>
  </id_info>
  <brief_title>Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer</brief_title>
  <official_title>A Multicenter Clinical Registry to Compare Different Patterns of Response Evaluation to Neoadjuvant Chemotherapy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Neoadjuvant chemotherapy has been proved effective for locally advanced gastric&#xD;
      cancer, yet the best pattern of response evaluation remain unknown.&#xD;
&#xD;
      PURPOSE: Compare different pattern of response evaluation for Gastric Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Find the best pattern for response evaluation for gastric cancer. II. Assess&#xD;
      the factor associated with this pattern.&#xD;
&#xD;
      OUTLINE: Neoadjuvant chemotherapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: Up to 150 patients will be accrued over approximately 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Pathological Response</measure>
    <time_frame>7days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>downstage proportion</measure>
    <time_frame>7days</time_frame>
    <description>compared pathological stage with initial clinical stage, define T downstage or N downstage as downstage</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy</arm_group_label>
    <description>undergo neoadjuvant chemotherapy before surgery</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor, Blood Sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Locally advanced Gastric Cancer(cT2-4NanyM0)，estimated to do neoadjuvant chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sign written informed consent form&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  pathologically confirmed gastric or GEJ adenocarcinoma&#xD;
&#xD;
          -  disease at clinical stage of locally advanced gastric cancer by CT/EUS(cT2+NanyM0)&#xD;
&#xD;
          -  No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune&#xD;
             therapy or target therapy&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
        Hematologic ANC ≥ 1.5*109/l Hemoglobin ≥ 9 g/dl Platelets ≥ 100*109/l Hepatic Albumin ≥&#xD;
        30g/l Serum bilirubin ≤ 1.5×ULN AST and ALT ≤ 2.5×ULN ALP ≤ 2.5×ULN TBIL ≤ 1.5×ULN Renal&#xD;
        Serum Creatinine &lt; 1.5 ULN&#xD;
&#xD;
          -  KPS ≥ 70&#xD;
&#xD;
          -  Adequate lung and heart function&#xD;
&#xD;
          -  Negative serum or urine pregnant test within 7 days prior to randomization for&#xD;
             child-bearing age women&#xD;
&#xD;
          -  Sexually active males or females willing to practice contraception during the study&#xD;
             until 30 days after end of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to provide blood/tissue sample；&#xD;
&#xD;
          -  With distant metastasis diagnosed by CT/EUS；&#xD;
&#xD;
          -  Sexually active males or females refuse to practice contraception during the study&#xD;
             until 30 days after end of study.&#xD;
&#xD;
          -  History of organ transplantation（including autologous bone marrow transplantation and&#xD;
             Peripheral stem cell transplantation）；&#xD;
&#xD;
          -  Prior long term steroid therapy (excluding short term steroid treatment which is&#xD;
             completed prior to &gt; 2 weeks of study enrollment)；&#xD;
&#xD;
          -  Patients with central nervous system(CNS) disorder or peripheral nervous system&#xD;
             disorder or psychiatric disease；&#xD;
&#xD;
          -  Concurrent severe infection；&#xD;
&#xD;
          -  Concurrent disease or condition that would make the subject inappropriate for study&#xD;
             participation or any serious medical disorder that would interfere with the subject's&#xD;
             safety (including current active hepatic, biliary, renal, respiratory disease,&#xD;
             uncontrolled diabetes hypertension et al)；&#xD;
&#xD;
          -  History of other malignancy. However, subjects who have been disease-free for 5 years,&#xD;
             or subjects with a history of completely resected non-melanoma skin cancer or&#xD;
             successfully treated in situ carcinoma, are eligible；&#xD;
&#xD;
          -  Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and&#xD;
             hypertension, or congestive heart failure, or cardiac infarction within 6 months prior&#xD;
             to study enrollment, or cardiac insufficiency；&#xD;
&#xD;
          -  Person with no capacity (legally) or inappropriate to continue study treatment for&#xD;
             ethics/medical reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiafu Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiafu Ji, MD</last_name>
    <phone>86-10-88196050</phone>
    <email>jiafuj@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Unicersity Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiafu Ji, MD</last_name>
      <phone>0086-10-88196391</phone>
      <email>jiafuj@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>June 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>December 6, 2014</last_update_submitted>
  <last_update_submitted_qc>December 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jiafu Ji</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Response Evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

